Join us for an insightful conversation on hMPV featuring our Chief Scientific Officer, Dr Andrew Catchpole and Guy Boivin, a professor from Laval University and one of the founding fathers
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
Zak Mir interviews Poolbeg Pharma’s CEO Jeremy Skillington & Principal Scientist Liam Tremble
Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk’s Zak Mir about the company’s conference season.
hVIVO plc (AIM: HVO) Positive data from novel human challenge models
Positive data from multiple novel human challenge models hVIVO presentations made at influential ESWI and World Vaccine Congress Europe conferences
hVIVO plc (AIM: HVO) Presentation at Jefferies Healthcare Conference
hVIVO to present at Jefferies Global Healthcare Conference
European Green Transition (AIM: EGT) Option Agreement to Sell Pajala Copper Project
European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces that it has entered into an exclusive
European Green Transition (AIM: EGT) Appointment of Independent Non-Executive Director
European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces the appointment of Mick Kearney as an
Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones
European Green Transition: From Exploration to Execution at The Investor Summit
A Company in Transition
Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update
ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK
European Green Transition (AIM: EGT) Interim results and M&A strategy update
European Green Transition (AIM: EGT), a company which aims to capitalise on the opportunities created by the green energy transition in Europe, announces its unaudited results for the six months